<DOC>
	<DOCNO>NCT01948895</DOCNO>
	<brief_summary>This multi-centred study conduct two centre . The design open label , flexible-dose study . This investigation evaluate efficacy Desvenlafaxine monotherapy patient meet diagnostic criterion dysthymia .</brief_summary>
	<brief_title>Desvenlafaxine Monotherapy Dysthymia</brief_title>
	<detailed_description>Primary objective : To investigate efficacy , safety , tolerability open-label desvenlafaxine monotherapy dysthymic subject . Secondary objective : To evaluate efficacy desvenlafaxine clinical measure relate improvement depressive symptom , quality life occupational functioning . It hypothesize Dysthymic subject show significant improvement depressive symptom 8 week treatment desvenlafaxine . There significant improvement measure quality life stress cop end treatment , compare Baseline . There also significant improvement measure occupational functioning end treatment , compare Baseline .</detailed_description>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Male female patient 1865 year . Primary diagnosis Dysthymic Disorder , define DSMIV criterion ( 300.4 ) . MADRS score â‰¥15 Screening Baseline . Supportive therapy , use zopiclone sleep lowdose benzodiazepine need basis anxiety , allow time . Written inform consent Comorbid diagnosis Axis I disorder ( anxiety disorder Generalized Anxiety Disorder , Social Anxiety Disorder Posttraumatic Stress Disorder , provide Dysthymic Disorder currently diagnosis ) . Meet DSMIV criterion current episode major depression within two month prior screen receive treatment major depressive episode within six month prior screen . Substance abuse dependence include alcohol , within 6 month prior screen . Patients follow prohibited treatment : 1 . Psychotropics SSRIs , SNRIs , lithium , sibutramine , tramadol , St. John 's Wort , within 2 week randomization 2 . Agents impact significantly serotonin metabolism ( e.g . MAOIs , tryptophan , triptans ) within 2 week randomization Have receive physical therapy depression ( e.g . ECT , rTMS ) within 3 month prior randomization . Previous nonresponse therapeutic trial desvenlafaxine ( least 50 mg/day 2 month ) . Clinically significant abnormality hematology , clinical chemistry , urinalysis ECG screen visit , judge Principal Investigator . Presence medical psychiatric condition deem Investigator interfere study procedure endpoint data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Desvenlafaxine</keyword>
	<keyword>Open-label</keyword>
	<keyword>Flexible-dose</keyword>
	<keyword>Dysthymic disorder</keyword>
	<keyword>Anxiety disorder</keyword>
	<keyword>Generalized anxiety disorder</keyword>
	<keyword>Social anxiety disorder</keyword>
	<keyword>Post-traumatic stress disorder</keyword>
</DOC>